Spring Creek Capital’s Pfizer PFE Stock Holding History

Spring Creek Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-71,718	Closed	-$2.47M	–	504
2018 Q2	$2.47M	Buy	+71,718	New	+$2.45M	0.29%	28

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Spring Creek Capital's PFE Position: Q3 2018 in Review

Spring Creek Capital sold out of Pfizer (PFE) in Q3 2018, closing a stake of 71,718 shares — an estimated $2.47M sold.

Spring Creek Capital first reported a position in PFE in Q2 2018 and held it in 1 quarter. The position peaked at $2.47M in Q2 2018. 2,256 funds tracked by Wall St. Rank hold PFE as of Q3 2018.

Spring Creek Capital reported no remaining Pfizer position as of Q3 2018 after selling out during the quarter.
Spring Creek Capital sold 71,718 Pfizer shares in Q3 2018, an estimated $2.47M.
Spring Creek Capital first reported a position in Pfizer in Q2 2018 and held it in 1 quarter.
Spring Creek Capital's Pfizer position peaked at $2.47M in Q2 2018.
2,256 funds tracked by Wall St. Rank held Pfizer as of Q3 2018.

Based on Spring Creek Capital's 13F filing for Q3 2018, filed 13 Nov 2018.